These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38715343)

  • 21. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients.
    Cao H; Su S; Yang Q; Le Y; Chen L; Hu M; Guo X; Zheng J; Li X; Yu Y
    Lipids Health Dis; 2021 Feb; 20(1):16. PubMed ID: 33602246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral fumaric acid esters for psoriasis.
    Atwan A; Ingram JR; Abbott R; Kelson MJ; Pickles T; Bauer A; Piguet V
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010497. PubMed ID: 26258748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment.
    Chládek J; Martínková J; Simková M; Vanecková J; Koudelková V; Nozicková M
    Eur J Clin Pharmacol; 1998 Feb; 53(6):437-44. PubMed ID: 9551702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
    Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients.
    Chen M; Chen W; Liu P; Yan K; Lv C; Zhang M; Lu Y; Qin Q; Kuang Y; Zhu W; Chen X
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2059-2065. PubMed ID: 32271961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TWEAK levels in psoriatic patients treated with narrowband ultraviolet B and methotrexate.
    Hegazy EM; El Taieb MA; Ibrahim HM; Rageh EM; Ahmed NM; Ibrahim AK; Younis AM; Ali MA
    J Cosmet Dermatol; 2024 May; 23(5):1905-1911. PubMed ID: 38299446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis.
    Dogra S; Singh N; Kumar S; Narang T; Handa S
    Dermatol Ther; 2022 Aug; 35(8):e15656. PubMed ID: 35730664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
    Chládek J; Simková M; Vanecková J; Hroch M; Vávrová J; Hůlek P
    J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):1007-14. PubMed ID: 22882190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TST conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients.
    de Medeiros VLS; Santos FCF; Montenegro LML; Silva MDC; Souza VMO; Lima Neto RG; Moura LCRV; Magalhães V
    PLoS One; 2020; 15(12):e0242098. PubMed ID: 33270676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study.
    Rivera R; Vilarrasa E; Ribera M; Roe E; Kueder-Pajares T; Zayas AI; Martínez-Molina L; Mataix Díaz J; Rodríguez-Nevado IM; Usero-Bárcena T; de la Mano D; García-Donoso C; Olveira A; Guinea G; Martín-Vázquez V; Ferran M
    J Dermatolog Treat; 2022 May; 33(3):1329-1338. PubMed ID: 32900254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis.
    Attwa EM; Elkot RA; Abdelshafey AS; Hafez AR
    Dermatol Ther; 2019 Sep; 32(5):e13051. PubMed ID: 31381231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
    van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
    Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of methotrexate monotherapy on T-cell subsets in the peripheral circulation in psoriasis.
    Priyadarssini M; Chandrashekar L; Rajappa M
    Clin Exp Dermatol; 2019 Jul; 44(5):491-497. PubMed ID: 30294828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children.
    Rahman SI; Siegfried E; Flanagan KH; Armbrecht ES
    J Am Acad Dermatol; 2014 Feb; 70(2):252-6. PubMed ID: 24332314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.
    Inzinger M; Weger W; Heschl B; Salmhofer W; Quehenberger F; Wolf P
    J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):861-6. PubMed ID: 22672248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
    Shah S; Nikam B; Kale M; Jamale V; Chavan D
    Dermatol Ther; 2021 Jan; 34(1):e14650. PubMed ID: 33296549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unlocking the role of the B7-H4 polymorphism in psoriasis: Insights into methotrexate treatment outcomes: A prospective cohort study.
    Wang B; Wang Z; Yang W; Han L; Huang Q; Yawalkar N; Zhang Z; Yao Y; Yan K
    Immunology; 2024 Jan; 171(1):104-116. PubMed ID: 37814391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.